Gilead Sciences (GILD) Change in Account Payables (2009 - 2026)

Gilead Sciences (GILD) has reported Change in Account Payables for 18 consecutive years, with -$67.0 million the latest figure, recorded in Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$67.0 million, up 36.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$94.0 million (down 183.19% YoY), and the FY2025 annual result was -$132.0 million, down 145.52% from the prior year.
• Change in Account Payables was -$67.0 million for Q1 2026 at Gilead Sciences, up from -$95.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $359.0 million in Q3 2024 and troughed at -$272.0 million in Q1 2023.
• Average Change in Account Payables over 5 years is -$1.8 million, with a median of -$43.0 million recorded in 2023.
• The widest YoY moves for Change in Account Payables: up 1337.93% in 2024, down 2666.67% in 2024.
• Over 5 years, Change in Account Payables stood at $264.0 million in 2022, then plunged by 116.29% to -$43.0 million in 2023, then slumped by 34.88% to -$58.0 million in 2024, then tumbled by 63.79% to -$95.0 million in 2025, then rose by 29.47% to -$67.0 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were -$67.0 million in Q1 2026, -$95.0 million in Q4 2025, and $230.0 million in Q3 2025.